(19) |
|
|
(11) |
EP 2 380 566 A3 |
(12) |
EUROPEAN PATENT APPLICATION |
(88) |
Date of publication A3: |
|
11.04.2012 Bulletin 2012/15 |
(43) |
Date of publication A2: |
|
26.10.2011 Bulletin 2011/43 |
(22) |
Date of filing: 14.09.2007 |
|
(51) |
International Patent Classification (IPC):
|
|
(84) |
Designated Contracting States: |
|
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO
SE SI SK TR |
(30) |
Priority: |
15.09.2006 DK 200601200 06.09.2007 DK 200701274
|
(62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
07801392.7 / 2068853 |
(71) |
Applicant: Stevia APS |
|
2820 Gentofte (DK) |
|
(72) |
Inventors: |
|
- Hermansen, Kjeld
8250 Egå (DK)
- Jeppesen, Per Bendix
8250 Egå (DK)
|
(74) |
Representative: Høiberg A/S |
|
St. Kongensgade 59 A 1264 Copenhagen K 1264 Copenhagen K (DK) |
|
|
|
(54) |
Treatment of insulin resistance or diseases associated with insulin resistance using
steviol or isosteviol |
(57) The present invention relates to the use of a substance with the core structure of
formula (I), or pharmaceutically acceptable salts, solvates or prodrugs thereof, for
the manufacture of a composition for the treatment of insulin resistance or diseases
associated with insulin resistance, preferably in human subject in a daily dosage
in a range of from about 5 mg to about 1500 mg. The invention furthermore relates
to a method of treating insulin resistance or diseases associated with insulin resistance
in a mammal, said method comprises administering to said mamma, preferably a human
subject, a substance with the core structure of formula (I), preferably in a daily
dosage in a range from about 5 mg to about 1500 mg. The substance is preferably isosteviol
or steviol, or pharmaceutically acceptable salts, solvates or prodrugs thereof. Examples
of diseases associated with insulin resistance are e.g. type 2 diabetes mellitus,
insulin resistance syndrome, impaired glucose tolerance, the metabolic syndrome, hyperglycemia,
hyperinsulinemia, arteriosclerosis, hypercholesterolemia, hypertriglyceridemia, hyperlipidemia,
dyslipidemia, obesity, central obesity, polycystic ovarian syndrome, hypercoagulability,
hypertension, microalbuminuria, or any combinations thereof.